ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Liposomal Doxorubicin Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
Published Date: June 2025
|
Report Code: QYRE-Auto-39C8806
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global Liposomal Doxorubicin Market Outlook 2022
BUY CHAPTERS

Global Liposomal Doxorubicin Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031

Code: QYRE-Auto-39C8806
Report
June 2025
Pages:131
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Johnson & Johnson
Sun Pharmaceutical
CSPC
Kinyond
TEVA
Fudan-Zhangjiang
Zydus Cadila
TTY Biopharma

Liposomal Doxorubicin Market Size

In 2024, the global market size of Liposomal Doxorubicin was estimated to be worth US$ 1474 million and is forecast to reach approximately US$ 2461 million by 2031 with a CAGR of 7.7% during the forecast period 2025-2031.

Liposomal Doxorubicin Market

Liposomal Doxorubicin Market

Liposome doxorubicin is a commonly used anthracycline anti-tumor drug, and is one of the first-line drugs for ovarian cancer.
Market competition is intense. Johnson & Johnson, Sun Pharmaceutical, CSPC, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers. Top 3 accounted for 60.41% market share.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Liposomal Doxorubicin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Liposomal Doxorubicin.
The Liposomal Doxorubicin market size, estimations, and forecasts are provided in terms of sales volume (K Unit) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Liposomal Doxorubicin market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Liposomal Doxorubicin manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and regions.

Scope of Liposomal Doxorubicin Market Report

Report Metric Details
Report Name Liposomal Doxorubicin Market
CAGR 7.7%
Segment by Type
  • 5 ml
  • 10 ml
  • 25 ml
Segment by Application
  • Breast Cancer
  • Liver Cancer
  • Kidney Cancer
  • Multiple Myeloma
  • Ovarian Cancer
  • Other
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Johnson & Johnson, Sun Pharmaceutical, CSPC, Kinyond, Teva, Fudan-Zhangjiang, Zydus Cadila, TTY Biopharma
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Sales (consumption), revenue of Liposomal Doxorubicin in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
  • Chapter 3: Detailed analysis of Liposomal Doxorubicin manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Liposomal Doxorubicin sales, revenue, price, gross margin, sales by region, by Type, by Application, and recent development, etc.
  • Chapter 5: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 6: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 7: North America by Type, by Application and by country, sales, and revenue for each segment.
  • Chapter 8: APAC by Type, by Application and by country, sales, and revenue for each segment.
  • Chapter 9: Europe by Type, by Application and by country, sales, and revenue for each segment.
  • Chapter 10: Latin America by Type, by Application and by country, sales, and revenue for each segment.
  • Chapter 11: Middle East and Africa by Type, by Application and by country, sales, and revenue for each segment.
  • Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
  • Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 14: Research Findings and Conclusion.

FAQ for this report

Who are the main players in the Liposomal Doxorubicin Market report?

Ans: The main players in the Liposomal Doxorubicin Market are Johnson & Johnson, Sun Pharmaceutical, CSPC, Kinyond, Teva, Fudan-Zhangjiang, Zydus Cadila, TTY Biopharma

What are the Application segmentation covered in the Liposomal Doxorubicin Market report?

Ans: The Applications covered in the Liposomal Doxorubicin Market report are Breast Cancer, Liver Cancer, Kidney Cancer, Multiple Myeloma, Ovarian Cancer, Other

What are the Type segmentation covered in the Liposomal Doxorubicin Market report?

Ans: The Types covered in the Liposomal Doxorubicin Market report are 5 ml, 10 ml, 25 ml

1 Study Coverage
1.1 Liposomal Doxorubicin Product Introduction
1.2 Market by Type
1.2.1 Global Liposomal Doxorubicin Market Size Growth Rate by Type (2020 VS 2024 VS 2031)
1.2.2 5 ml
1.2.3 10 ml
1.2.4 25 ml
1.3 Market by Application
1.3.1 Global Liposomal Doxorubicin Market Size Growth Rate by Application (2020 VS 2024 VS 2031)
1.3.2 Breast Cancer
1.3.3 Liver Cancer
1.3.4 Kidney Cancer
1.3.5 Multiple Myeloma
1.3.6 Ovarian Cancer
1.3.7 Other
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Liposomal Doxorubicin Market Size Estimates and Forecasts
2.1.1 Global Liposomal Doxorubicin Revenue 2020-2031
2.1.2 Global Liposomal Doxorubicin Sales 2020-2031
2.2 Liposomal Doxorubicin Market Size by Region: 2024 Versus 2031
2.3 Liposomal Doxorubicin Sales by Region (2020-2031)
2.3.1 Global Liposomal Doxorubicin Sales by Region: 2020-2025
2.3.2 Global Liposomal Doxorubicin Sales Forecast by Region (2026-2031)
2.3.3 Global Liposomal Doxorubicin Sales Market Share by Region (2020-2031)
2.4 Liposomal Doxorubicin Market Estimates and Projections by Region (2026-2031)
2.4.1 Global Liposomal Doxorubicin Revenue by Region: 2020-2025
2.4.2 Global Liposomal Doxorubicin Revenue Forecast by Region (2026-2031)
2.4.3 Global Liposomal Doxorubicin Revenue Market Share by Region (2020-2031)
3 Market Segments
3.1 Breakdown Data by Type
3.1.1 Global Liposomal Doxorubicin Sales by Type (2020-2031)
3.1.1.1 Global Liposomal Doxorubicin Sales Volume by Type (2020-2031)
3.1.1.2 Global Liposomal Doxorubicin Sales Market Share by Type (2020-2031)
3.1.2 Global Liposomal Doxorubicin Revenue by Type (2020-2031)
3.1.2.1 Global Liposomal Doxorubicin Revenue by Type (2020-2031)
3.1.2.2 Global Liposomal Doxorubicin Revenue Market Share by Type (2020-2031)
3.1.3 Liposomal Doxorubicin Average Selling Price (ASP) by Type (2020-2031)
3.2 Breakdown Data by Application
3.2.1 Global Liposomal Doxorubicin Sales by Application (2020-2031)
3.2.1.1 Global Liposomal Doxorubicin Sales Volume by Application (2020-2031)
3.2.1.2 Global Liposomal Doxorubicin Sales Market Share by Application (2020-2031)
3.2.2 Global Liposomal Doxorubicin Revenue by Application (2020-2031)
3.2.2.1 Global Liposomal Doxorubicin Revenue by Application (2020-2031)
3.2.2.2 Global Liposomal Doxorubicin Revenue Market Share by Application (2020-2031)
3.2.3 Liposomal Doxorubicin Average Selling Price (ASP) by Application (2020-2031)
3.3 by Type and by Application Crossing Analysis
3.3.1 5 ml of Liposomal Doxorubicin Revenue Market Share by Application
3.3.2 10 ml of Liposomal Doxorubicin Revenue Market Share by Application
3.3.3 25 ml of Liposomal Doxorubicin Revenue Market Share by Application
4 Global Liposomal Doxorubicin by Manufacturers
4.1 Global Top Liposomal Doxorubicin Manufacturers by Sales (2020-2025)
4.1.1 Global Liposomal Doxorubicin Sales by Manufacturer (2020-2025)
4.1.2 Global Liposomal Doxorubicin Sales Market Share by Manufacturer (2020-2025)
4.2 Global Top Liposomal Doxorubicin Manufacturers by Revenue (2020-2025)
4.2.1 Global Liposomal Doxorubicin Revenue by Manufacturer (2020-2025)
4.2.2 Global Liposomal Doxorubicin Revenue Share by Manufacturer (2020-2025)
4.3 Global Liposomal Doxorubicin Price by Manufacturer (2020-2025)
4.4 Competitive Landscape
4.4.1 Key Liposomal Doxorubicin Manufacturers Covered: Ranking by Revenue
4.4.2 Global Liposomal Doxorubicin Market Concentration Ratio (CR5 and HHI) & (2020-2025)
4.4.3 Global Liposomal Doxorubicin Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.5 Global Liposomal Doxorubicin Manufacturing Base Distribution, Product Type
4.5.1 Liposomal Doxorubicin Manufacturers Manufacturing Base Distribution, Headquarters
4.5.2 Date of International Manufacturers Enter into Liposomal Doxorubicin Market
4.5.3 Manufacturers Liposomal Doxorubicin Product Type and Application
4.5.4 5 ml Market Sales of Liposomal Doxorubicin by Manufacturer
4.5.5 10 ml Market Sales of Liposomal Doxorubicin by Manufacturer
4.5.6 25 ml Market Sales of Liposomal Doxorubicin by Manufacturer
4.6 Manufacturers Mergers & Acquisitions, Expansion Plans
5 Company Profiles
5.1 Johnson & Johnson
5.1.1 Johnson & Johnson Company Information
5.1.2 Johnson & Johnson Description, Business Overview
5.1.3 Johnson & Johnson Liposomal Doxorubicin Products Offered
5.1.4 Johnson & Johnson Liposomal Doxorubicin Sales, Revenue and Gross Margin (2020-2025)
5.1.5 Johnson & Johnson Liposomal Doxorubicin Sales by Product in 2024
5.1.6 Johnson & Johnson Liposomal Doxorubicin Sales by Application in 2024
5.1.7 Johnson & Johnson Liposomal Doxorubicin Sales by Geographic Area in 2024
5.1.8 Johnson & Johnson Recent Developments
5.2 Sun Pharmaceutical
5.2.1 Sun Pharmaceutical Company Information
5.2.2 Sun Pharmaceutical Description, Business Overview
5.2.3 Sun Pharmaceutical Liposomal Doxorubicin Products Offered
5.2.4 Sun Pharmaceutical Liposomal Doxorubicin Sales, Revenue and Gross Margin (2020-2025)
5.2.5 Sun Pharmaceutical Liposomal Doxorubicin Sales by Product in 2024
5.2.6 Sun Pharmaceutical Liposomal Doxorubicin Sales by Application in 2024
5.2.7 Sun Pharmaceutical Liposomal Doxorubicin Sales by Geographic Area in 2024
5.2.8 Sun Pharmaceutical Recent Developments
5.3 CSPC
5.3.1 CSPC Company Information
5.3.2 CSPC Description, Business Overview
5.3.3 CSPC Liposomal Doxorubicin Products Offered
5.3.4 CSPC Liposomal Doxorubicin Sales, Revenue and Gross Margin (2020-2025)
5.3.5 CSPC Liposomal Doxorubicin Sales by Product in 2024
5.3.6 CSPC Liposomal Doxorubicin Sales by Application in 2024
5.3.7 CSPC Liposomal Doxorubicin Sales by Geographic Area in 2024
5.3.8 CSPC Recent Developments
5.4 Kinyond
5.4.1 Kinyond Company Information
5.4.2 Kinyond Description, Business Overview
5.4.3 Kinyond Liposomal Doxorubicin Products Offered
5.4.4 Kinyond Liposomal Doxorubicin Sales, Revenue and Gross Margin (2020-2025)
5.4.5 Kinyond Liposomal Doxorubicin Sales by Product in 2024
5.4.6 Kinyond Liposomal Doxorubicin Sales by Application in 2024
5.4.7 Kinyond Liposomal Doxorubicin Sales by Geographic Area in 2024
5.4.8 Kinyond Recent Developments
5.5 Teva
5.5.1 Teva Company Information
5.5.2 Teva Description, Business Overview
5.5.3 Teva Liposomal Doxorubicin Products Offered
5.5.4 Teva Liposomal Doxorubicin Sales, Revenue and Gross Margin (2020-2025)
5.5.5 Teva Liposomal Doxorubicin Sales by Product in 2024
5.5.6 Teva Liposomal Doxorubicin Sales by Application in 2024
5.5.7 Teva Liposomal Doxorubicin Sales by Geographic Area in 2024
5.5.8 Teva Recent Developments
5.6 Fudan-Zhangjiang
5.6.1 Fudan-Zhangjiang Company Information
5.6.2 Fudan-Zhangjiang Description, Business Overview
5.6.3 Fudan-Zhangjiang Liposomal Doxorubicin Products Offered
5.6.4 Fudan-Zhangjiang Liposomal Doxorubicin Sales, Revenue and Gross Margin (2020-2025)
5.6.5 Fudan-Zhangjiang Liposomal Doxorubicin Sales by Product in 2024
5.6.6 Fudan-Zhangjiang Liposomal Doxorubicin Sales by Application in 2024
5.6.7 Fudan-Zhangjiang Liposomal Doxorubicin Sales by Geographic Area in 2024
5.6.8 Fudan-Zhangjiang Recent Developments
5.7 Zydus Cadila
5.7.1 Zydus Cadila Company Information
5.7.2 Zydus Cadila Description, Business Overview
5.7.3 Zydus Cadila Liposomal Doxorubicin Products Offered
5.7.4 Zydus Cadila Liposomal Doxorubicin Sales, Revenue and Gross Margin (2020-2025)
5.7.5 Zydus Cadila Liposomal Doxorubicin Sales by Product in 2024
5.7.6 Zydus Cadila Liposomal Doxorubicin Sales by Application in 2024
5.7.7 Zydus Cadila Liposomal Doxorubicin Sales by Geographic Area in 2024
5.7.8 Zydus Cadila Recent Developments
5.8 TTY Biopharma
5.8.1 TTY Biopharma Company Information
5.8.2 TTY Biopharma Description, Business Overview
5.8.3 TTY Biopharma Liposomal Doxorubicin Products Offered
5.8.4 TTY Biopharma Liposomal Doxorubicin Sales, Revenue and Gross Margin (2020-2025)
5.8.5 TTY Biopharma Liposomal Doxorubicin Sales by Product in 2024
5.8.6 TTY Biopharma Liposomal Doxorubicin Sales by Application in 2024
5.8.7 TTY Biopharma Liposomal Doxorubicin Sales by Geographic Area in 2024
5.8.8 TTY Biopharma Recent Developments
6 North America
6.1 North America Liposomal Doxorubicin Market Size YoY Growth 2020-2031
6.2 North America Liposomal Doxorubicin Market Facts & Figures by Country
6.2.1 North America Liposomal Doxorubicin Sales by Country (2020-2031)
6.2.2 North America Liposomal Doxorubicin Revenue by Country (2020-2031)
6.3 North America Liposomal Doxorubicin Sales by Type (2020-2025)
6.4 North America Liposomal Doxorubicin Sales by Application (2020-2025)
7 Asia-Pacific
7.1 Asia-Pacific Liposomal Doxorubicin Market Size YoY Growth 2020-2031
7.2 Asia-Pacific Liposomal Doxorubicin Market Facts & Figures by Region
7.2.1 Asia-Pacific Liposomal Doxorubicin Sales by Region (2020-2031)
7.2.2 Asia-Pacific Liposomal Doxorubicin Revenue by Region (2020-2031)
7.3 Asia-Pacific Liposomal Doxorubicin Sales by Type (2020-2025)
7.4 Asia-Pacific Liposomal Doxorubicin Sales by Application (2020-2025)
8 Europe
8.1 Europe Liposomal Doxorubicin Market Size YoY Growth 2020-2031
8.2 Europe Liposomal Doxorubicin Market Facts & Figures by Country
8.2.1 Europe Liposomal Doxorubicin Sales by Country (2020-2031)
8.2.2 Europe Liposomal Doxorubicin Revenue by Country (2020-2031)
8.3 Europe Liposomal Doxorubicin Sales by Type (2020-2025)
8.4 Europe Liposomal Doxorubicin Sales by Application (2020-2025)
9 Latin America
9.1 Latin America Liposomal Doxorubicin Market Size YoY Growth 2020-2031
9.2 Latin America Liposomal Doxorubicin Market Facts & Figures by Country
9.2.1 Latin America Liposomal Doxorubicin Sales by Country (2020-2031)
9.2.2 Latin America Liposomal Doxorubicin Revenue by Country (2020-2031)
9.3 Latin America Liposomal Doxorubicin Sales by Type (2020-2025)
9.4 Latin America Liposomal Doxorubicin Sales by Application (2020-2025)
10 Middle East and Africa
10.1 Latin America Liposomal Doxorubicin Market Size YoY Growth 2020-2031
10.2 Middle East and Africa Liposomal Doxorubicin Market Facts & Figures by Country
10.2.1 Middle East and Africa Liposomal Doxorubicin Sales by Country (2020-2031)
10.2.2 Middle East and Africa Liposomal Doxorubicin Revenue by Country (2020-2031)
10.3 Middle East and Africa Liposomal Doxorubicin Sales by Type (2020-2025)
10.4 Middle East and Africa Liposomal Doxorubicin Sales by Application (2020-2025)
11 Supply Chain and Sales Channel analysis
11.1 Liposomal Doxorubicin Supply Chain Analysis
11.2 Liposomal Doxorubicin Key Raw Materials and Upstream Suppliers
11.3 Liposomal Doxorubicin Clients Analysis
11.4 Liposomal Doxorubicin Sales Channel and Sales Model Analysis
11.4.1 Liposomal Doxorubicin Distribution Channel Analysis: Indirect Sales VS Direct Sales
11.4.2 Liposomal Doxorubicin Distribution Channel Analysis: Online Sales VS Offline Sales
11.4.3 Liposomal Doxorubicin Distributors
12 Liposomal Doxorubicin Market Dynamics
12.1 Liposomal Doxorubicin Industry Trends
12.2 Liposomal Doxorubicin Market Drivers
12.3 Liposomal Doxorubicin Market Challenges
12.4 Liposomal Doxorubicin Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
FEATURED COMPANIES
Johnson & Johnson
Sun Pharmaceutical
CSPC
Kinyond
TEVA
Fudan-Zhangjiang
Zydus Cadila
TTY Biopharma
List of Tables
 Table 1. Global Liposomal Doxorubicin Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Global Liposomal Doxorubicin Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 3. Global Liposomal Doxorubicin Market Size by Region (US$ Million): 2024 VS 2031
 Table 4. Global Liposomal Doxorubicin Sales by Region (2020-2025) & (K Unit)
 Table 5. Global Liposomal Doxorubicin Sales Forecast by Region (2026-2031) & (K Unit)
 Table 6. Global Liposomal Doxorubicin Revenue by Region (2020-2025) & (US$ Million)
 Table 7. Global Liposomal Doxorubicin Revenue Forecast by Region (2026-2031) & (US$ Million)
 Table 8. Global Liposomal Doxorubicin Sales Volume by Type (2020-2025) & (K Unit)
 Table 9. Global Liposomal Doxorubicin Sales Volume by Type (2026-2031) & (K Unit)
 Table 10. Global Liposomal Doxorubicin Revenue by Type (2020-2025) & (US$ Million)
 Table 11. Global Liposomal Doxorubicin Revenue Forecast by Type (2026-2031) & (US$ Million)
 Table 12. Global Liposomal Doxorubicin Sales Volume by Application (2020-2025) & (K Unit)
 Table 13. Global Liposomal Doxorubicin Sales Volume by Application (2026-2031) & (K Unit)
 Table 14. Global Liposomal Doxorubicin Revenue by Application (2020-2025) & (US$ Million)
 Table 15. Global Liposomal Doxorubicin Revenue by Application (2026-2031) & (US$ Million)
 Table 16. Global Liposomal Doxorubicin Sales by Manufacturer (2020-2025) & (K Unit)
 Table 17. Global Liposomal Doxorubicin Sales Share by Manufacturer (2020-2025)
 Table 18. Liposomal Doxorubicin Revenue by Manufacturer (2020-2025) & (US$ Million)
 Table 19. Liposomal Doxorubicin Revenue Share by Manufacturer (2020-2025)
 Table 20. Key Manufacturers Liposomal Doxorubicin Price (2020-2025) & (USD/Unit)
 Table 21. Ranking of Global Top Liposomal Doxorubicin Manufacturers by Revenue (US$ Million) in 2024
 Table 22. Global Liposomal Doxorubicin Manufacturers Market Concentration Ratio (CR5 and HHI) & (2020-2025)
 Table 23. Global Liposomal Doxorubicin by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Liposomal Doxorubicin as of 2024)
 Table 24. Liposomal Doxorubicin Manufacturers Manufacturing Base Distribution and Headquarters
 Table 25. Date of International Manufacturers Enter into Liposomal Doxorubicin Market
 Table 26. Manufacturers Liposomal Doxorubicin Product Type and Application
 Table 27. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 28. Johnson & Johnson Company Information
 Table 29. Johnson & Johnson Description and Business Overview
 Table 30. Johnson & Johnson Liposomal Doxorubicin Product
 Table 31. Johnson & Johnson Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 32. Johnson & Johnson Sales Proportion of Liposomal Doxorubicin by Product in 2024
 Table 33. Johnson & Johnson Sales Proportion of Liposomal Doxorubicin by Application in 2024
 Table 34. Johnson & Johnson Sales Proportion of Liposomal Doxorubicin by Geographic Area in 2024
 Table 35. Johnson & Johnson Recent Developments
 Table 36. Sun Pharmaceutical Company Information
 Table 37. Sun Pharmaceutical Description and Business Overview
 Table 38. Sun Pharmaceutical Liposomal Doxorubicin Product
 Table 39. Sun Pharmaceutical Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 40. Sun Pharmaceutical Sales Proportion of Liposomal Doxorubicin by Product in 2024
 Table 41. Sun Pharmaceutical Sales Proportion of Liposomal Doxorubicin by Application in 2024
 Table 42. Sun Pharmaceutical Sales Proportion of Liposomal Doxorubicin by Geographic Area in 2024
 Table 43. Sun Pharmaceutical Recent Developments
 Table 44. CSPC Company Information
 Table 45. CSPC Description and Business Overview
 Table 46. CSPC Liposomal Doxorubicin Product
 Table 47. CSPC Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 48. CSPC Sales Proportion of Liposomal Doxorubicin by Product in 2024
 Table 49. CSPC Sales Proportion of Liposomal Doxorubicin by Application in 2024
 Table 50. CSPC Sales Proportion of Liposomal Doxorubicin by Geographic Area in 2024
 Table 51. CSPC Recent Developments
 Table 52. Kinyond Company Information
 Table 53. Kinyond Description and Business Overview
 Table 54. Kinyond Liposomal Doxorubicin Product
 Table 55. Kinyond Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 56. Kinyond Sales Proportion of Liposomal Doxorubicin by Product in 2024
 Table 57. Kinyond Sales Proportion of Liposomal Doxorubicin by Application in 2024
 Table 58. Kinyond Sales Proportion of Liposomal Doxorubicin by Geographic Area in 2024
 Table 59. Kinyond Recent Developments
 Table 60. Teva Company Information
 Table 61. Teva Description and Business Overview
 Table 62. Teva Liposomal Doxorubicin Product
 Table 63. Teva Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 64. Teva Sales Proportion of Liposomal Doxorubicin by Product in 2024
 Table 65. Teva Sales Proportion of Liposomal Doxorubicin by Application in 2024
 Table 66. Teva Sales Proportion of Liposomal Doxorubicin by Geographic Area in 2024
 Table 67. Teva Recent Developments
 Table 68. Fudan-Zhangjiang Company Information
 Table 69. Fudan-Zhangjiang Description and Business Overview
 Table 70. Fudan-Zhangjiang Liposomal Doxorubicin Product
 Table 71. Fudan-Zhangjiang Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 72. Fudan-Zhangjiang Sales Proportion of Liposomal Doxorubicin by Product in 2024
 Table 73. Fudan-Zhangjiang Sales Proportion of Liposomal Doxorubicin by Application in 2024
 Table 74. Fudan-Zhangjiang Sales Proportion of Liposomal Doxorubicin by Geographic Area in 2024
 Table 75. Fudan-Zhangjiang Recent Developments
 Table 76. Zydus Cadila Company Information
 Table 77. Zydus Cadila Description and Business Overview
 Table 78. Zydus Cadila Liposomal Doxorubicin Product
 Table 79. Zydus Cadila Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 80. Zydus Cadila Sales Proportion of Liposomal Doxorubicin by Product in 2024
 Table 81. Zydus Cadila Sales Proportion of Liposomal Doxorubicin by Application in 2024
 Table 82. Zydus Cadila Sales Proportion of Liposomal Doxorubicin by Geographic Area in 2024
 Table 83. Zydus Cadila Recent Developments
 Table 84. TTY Biopharma Company Information
 Table 85. TTY Biopharma Description and Business Overview
 Table 86. TTY Biopharma Liposomal Doxorubicin Product
 Table 87. TTY Biopharma Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 88. TTY Biopharma Sales Proportion of Liposomal Doxorubicin by Product in 2024
 Table 89. TTY Biopharma Sales Proportion of Liposomal Doxorubicin by Application in 2024
 Table 90. TTY Biopharma Sales Proportion of Liposomal Doxorubicin by Geographic Area in 2024
 Table 91. TTY Biopharma Recent Developments
 Table 92. North America Liposomal Doxorubicin Sales by Country (2020-2025) & (K Unit)
 Table 93. North America Liposomal Doxorubicin Sales by Country (2026-2031) & (K Unit)
 Table 94. North America Liposomal Doxorubicin Revenue by Country (2020-2025) & (US$ Million)
 Table 95. North America Liposomal Doxorubicin Revenue by Country (2026-2031) & (US$ Million)
 Table 96. North America Liposomal Doxorubicin Sales by Type (2020-2025) & (K Unit)
 Table 97. North America Liposomal Doxorubicin Sales by Application (2020-2025) & (K Unit)
 Table 98. Asia-Pacific Liposomal Doxorubicin Sales by Region (2020-2025) & (K Unit)
 Table 99. Asia-Pacific Liposomal Doxorubicin Sales by Region (2026-2031) & (K Unit)
 Table 100. Asia-Pacific Liposomal Doxorubicin Revenue by Region (2020-2025) & (US$ Million)
 Table 101. Asia-Pacific Liposomal Doxorubicin Revenue by Region (2026-2031) & (US$ Million)
 Table 102. Asia-Pacific Liposomal Doxorubicin Sales by Type (2020-2025) & (K Unit)
 Table 103. Asia-Pacific Liposomal Doxorubicin Sales by Application (2020-2025) & (K Unit)
 Table 104. Europe Liposomal Doxorubicin Sales by Country (2020-2025) & (K Unit)
 Table 105. Europe Liposomal Doxorubicin Sales by Country (2026-2031) & (K Unit)
 Table 106. Europe Liposomal Doxorubicin Revenue by Country (2020-2025) & (US$ Million)
 Table 107. Europe Liposomal Doxorubicin Revenue by Country (2026-2031) & (US$ Million)
 Table 108. Europe Liposomal Doxorubicin Sales by Type (2020-2025) & (K Unit)
 Table 109. Europe Liposomal Doxorubicin Sales by Application (2020-2025) & (K Unit)
 Table 110. Latin America Liposomal Doxorubicin Sales by Country (2020-2025) & (K Unit)
 Table 111. Latin America Liposomal Doxorubicin Sales by Country (2026-2031) & (K Unit)
 Table 112. Latin America Liposomal Doxorubicin Revenue by Country (2020-2025) & (US$ Million)
 Table 113. Latin America Liposomal Doxorubicin Revenue by Country (2026-2031) & (US$ Million)
 Table 114. Latin America Liposomal Doxorubicin Sales by Type (2020-2025) & (K Unit)
 Table 115. Latin America Liposomal Doxorubicin Sales by Application (2020-2025) & (K Unit)
 Table 116. Middle East and Africa Liposomal Doxorubicin Sales by Country (2020-2025) & (K Unit)
 Table 117. Middle East and Africa Liposomal Doxorubicin Sales by Country (2026-2031) & (K Unit)
 Table 118. Middle East and Africa Liposomal Doxorubicin Revenue by Country (2020-2025) & (US$ Million)
 Table 119. Middle East and Africa Liposomal Doxorubicin Revenue by Country (2026-2031) & (US$ Million)
 Table 120. Middle East and Africa Liposomal Doxorubicin Sales by Type (2020-2025) & (K Unit)
 Table 121. Middle East and Africa Liposomal Doxorubicin Sales by Application (2020-2025) & (K Unit)
 Table 122. Liposomal Doxorubicin Key Raw Materials, Industry Status and Trend
 Table 123. Liposomal Doxorubicin Key Raw Materials and Upstream Suppliers
 Table 124. Liposomal Doxorubicin Clients Status and Trend
 Table 125. Liposomal Doxorubicin Typical Clients
 Table 126. Liposomal Doxorubicin Distributors
 Table 127. Liposomal Doxorubicin Market Trends
 Table 128. Liposomal Doxorubicin Market Drivers
 Table 129. Liposomal Doxorubicin Market Challenges
 Table 130. Liposomal Doxorubicin Market Restraints
 Table 131. Research Programs/Design for This Report
 Table 132. Key Data Information from Secondary Sources
 Table 133. Key Data Information from Primary Sources
 Table 134. QYR Business Unit and Senior & Team Lead Analysts


List of Figures
 Figure 1. Liposomal Doxorubicin Product Picture
 Figure 2. Global Liposomal Doxorubicin Market Size by Type (US$ Million): 2020 VS 2024 VS 2031
 Figure 3. Global Liposomal Doxorubicin Sales Market Share by Type in 2024 & 2031
 Figure 4. 5 ml Product Picture
 Figure 5. 10 ml Product Picture
 Figure 6. 25 ml Product Picture
 Figure 7. Global Liposomal Doxorubicin Market Size by Application (US$ Million): 2020 VS 2024 VS 2031
 Figure 8. Global Liposomal Doxorubicin Sales Market Share by Application in 2024 & 2031
 Figure 9. Breast Cancer
 Figure 10. Liver Cancer
 Figure 11. Kidney Cancer
 Figure 12. Multiple Myeloma
 Figure 13. Ovarian Cancer
 Figure 14. Other
 Figure 15. Liposomal Doxorubicin Report Years Considered
 Figure 16. Global Liposomal Doxorubicin Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 17. Global Liposomal Doxorubicin Market Size 2020-2031 (US$ Million)
 Figure 18. Global Liposomal Doxorubicin Sales 2020-2031 (K Unit)
 Figure 19. Global Liposomal Doxorubicin Sales Market Share Forecast by Region (2020-2031)
 Figure 20. Global Liposomal Doxorubicin Revenue Market Share by Region (2020-2031)
 Figure 21. Global Liposomal Doxorubicin Sales Market Share Forecast by Type (2020-2031)
 Figure 22. Global Liposomal Doxorubicin Revenue Market Share Forecast by Type (2020-2031)
 Figure 23. Liposomal Doxorubicin Average Selling Price (ASP) by Type (2020-2025) & (USD/Unit)
 Figure 24. Global Liposomal Doxorubicin Sales Market Share Forecast by Application (2020-2031)
 Figure 25. Global Liposomal Doxorubicin Revenue Market Share Forecast by Application (2020-2031)
 Figure 26. Liposomal Doxorubicin Average Selling Price (ASP) by Application (2020-2025) & (USD/Unit)
 Figure 27. 5 ml of Liposomal Doxorubicin Revenue Market Share by Application, 2024 VS 2031
 Figure 28. 10 ml of Liposomal Doxorubicin Revenue Market Share by Application, 2024 VS 2031
 Figure 29. 25 ml of Liposomal Doxorubicin Revenue Market Share by Application, 2024 VS 2031
 Figure 30. Global Liposomal Doxorubicin Sales Share by Manufacturer in 2024
 Figure 31. Liposomal Doxorubicin Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 32. 5 ml Market Sales Proportion by Manufacturer in 2024
 Figure 33. 10 ml Market Sales Proportion by Manufacturer in 2024
 Figure 34. 25 ml Market Sales Proportion by Manufacturer in 2024
 Figure 35. North America Liposomal Doxorubicin Revenue 2020-2031 (US$ Million)
 Figure 36. North America Liposomal Doxorubicin Sales Market Share by Type (2020-2025)
 Figure 37. North America Liposomal Doxorubicin Sales Market Share by Application (2020-2025)
 Figure 38. Asia-Pacific Liposomal Doxorubicin Revenue 2020-2031 (US$ Million)
 Figure 39. Asia-Pacific Liposomal Doxorubicin Sales Market Share by Region (2020-2031)
 Figure 40. Asia-Pacific Liposomal Doxorubicin Revenue Market Share by Region (2020-2031)
 Figure 41. Asia-Pacific Liposomal Doxorubicin Sales Market Share by Type (2020-2025)
 Figure 42. Asia-Pacific Liposomal Doxorubicin Sales Market Share by Application (2020-2025)
 Figure 43. Europe Liposomal Doxorubicin Revenue Growth Rate 2020-2031 (US$ Million)
 Figure 44. Europe Liposomal Doxorubicin Sales Market Share by Country (2020-2031)
 Figure 45. Europe Liposomal Doxorubicin Revenue Market Share by Country (2020-2031)
 Figure 46. Europe Liposomal Doxorubicin Sales Market Share by Type (2020-2025)
 Figure 47. Europe Liposomal Doxorubicin Sales Market Share by Application (2020-2025)
 Figure 48. Latin America Liposomal Doxorubicin Revenue Growth Rate 2020-2031 (US$ Million)
 Figure 49. Latin America Liposomal Doxorubicin Sales Market Share by Country (2020-2031)
 Figure 50. Latin America Liposomal Doxorubicin Revenue Market Share by Country (2020-2025)
 Figure 51. Latin America Liposomal Doxorubicin Sales Market Share by Type (2020-2025)
 Figure 52. Latin America Liposomal Doxorubicin Sales Market Share by Application (2020-2025)
 Figure 53. Middle East and Africa Liposomal Doxorubicin Revenue Growth Rate 2020-2031 (US$ Million)
 Figure 54. Middle East and Africa Liposomal Doxorubicin Sales Market Share by Country (2020-2031)
 Figure 55. Middle East and Africa Liposomal Doxorubicin Revenue Market Share by Country (2020-2031)
 Figure 56. Middle East and Africa Liposomal Doxorubicin Sales Market Share by Type (2020-2025)
 Figure 57. Middle East and Africa Liposomal Doxorubicin Sales Market Share by Application (2020-2025)
 Figure 58. Liposomal Doxorubicin Supply Chain (Upstream and Downstream Market)
 Figure 59. Global Production Market Share of Liposomal Doxorubicin Raw Materials by Region in 2024
 Figure 60. Liposomal Doxorubicin Distribution Channels
 Figure 61. Global Liposomal Doxorubicin Percentage 2020-2031: Indirect Sales VS Direct Sales
 Figure 62. Global Liposomal Doxorubicin Percentage 2020-2031: Online Sales VS Offline Sales
 Figure 63. Bottom-up and Top-down Approaches for This Report
 Figure 64. Data Triangulation
 Figure 65. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$5900

This license allows only one user to access the PDF.
Electronic (PDF)

$8850

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$11800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Lukasiewicz Research Network

SIMILAR REPORTS

Global Pegylated Liposomal Doxorubicin Market Research Report 2025
Liposomal Paclitaxel Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Liposomal Daunorubicin and Cytarabine Market Research Report 2024
Anthracyclines Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Doxorubicin Injection Market Research Report 2024
Global Doxorubicin Hydrochloride Injection Market Research Report 2024
Liposomal Amikacin Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Pegylated Liposomal Docorubicin Market Insights Forecast to 2030
Liposomal Mifamurtide Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Liposome Development Service Market Research Report 2025
Global Liposome Assisted Drug Delivery Market Insights Forecast to 2030
Anthracycline Anticancer Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Liposomal Market Insights Forecast to 2030
Liposomal Drug delivery System Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Vyxeos Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Microsphere Liposomes Market Research Report 2024
Platinum Anti tumor Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Cytarabine and Daunorubicin Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Taxane Antineoplastic Drug Market Research Report 2024
Global Doxorubicin Hydrochloride Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions